Loading...
Propanc Biopharma, Inc.
PPCB•PNK
Healthcare
Biotechnology
$9.60
$-0.39(-3.90%)
Propanc Biopharma, Inc. (PPCB) Financial Performance & Income Statement Overview
Review Propanc Biopharma, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
13.54%
↑ 13.54%
Net Income Growth
41.84%
↑ 41.84%
Operating Cash Flow Growth
15.39%
↑ 15.39%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-3652.46%
↓ 3652.46%
ROIC
-296.34%
↓ 296.34%
Propanc Biopharma, Inc. (PPCB) Income Statement & Financial Overview
Review Propanc Biopharma, Inc.'s (PPCB) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $8317.00 | $5764.00 | $4773.00 |
| Gross Profit | $0.00 | -$8317.00 | -$5764.00 | -$4773.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $54388.00 | $61714.00 | $52390.00 | $65448.00 |
| SG&A Expenses | $158994.00 | $229076.00 | $207509.00 | $350646.00 |
| Operating Expenses | $213382.00 | $290790.00 | $259899.00 | $416094.00 |
| Total Costs & Expenses | $213382.00 | $290790.00 | $259899.00 | $420867.00 |
| Interest Income | $0.00 | $1.00 | $0.00 | $27.00 |
| Interest Expense | $118943.00 | $86230.00 | $90004.00 | $133141.00 |
| Depreciation & Amortization | $4332.00 | $5534.00 | $5764.00 | $4773.00 |
| EBITDA | -$306908.00 | -$262547.00 | -$263042.00 | -$389065.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$213382.00 | -$290790.00 | -$259899.00 | -$420870.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | -$216801.00 | -$63520.00 | -$98916.00 | -$106108.00 |
| Income Before Tax | -$430183.00 | -$354310.00 | -$358815.00 | -$526975.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | -$237.00 | -$275.00 |
| Net Income | -$430183.00 | -$354310.00 | -$358578.00 | -$540000.00 |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$32.23 | -$0.001 | $0.00 | -$0.009 |
| Diluted EPS | -$32.23 | -$0.001 | $0.00 | -$0.009 |
| Weighted Avg Shares Outstanding | $13347.00 | $590.94M | $478.80M | $59.64M |
| Weighted Avg Shares Outstanding (Diluted) | $13347.00 | $590.94M | $478.80M | $59.64M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan